1 results match your criteria: "New York. Harvard Stem Cell Institute[Affiliation]"
Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.
Clin Cancer Res
May 2015
Division of Hematology/Oncology, Department of Pediatric Oncology, Boston Children's Hospital, Dana-Farber-Cancer Institute, and Harvard Medical School, Boston, Massachusetts. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. Harvard Stem Cell Institute, Boston, Massachusetts.
Purpose: Histone deacetylase inhibitors (HDACi) have recently emerged as efficacious therapies that target epigenetic mechanisms in hematologic malignancies. One such hematologic malignancy, B-cell acute lymphoblastic leukemia (B-ALL), may be highly dependent on epigenetic regulation for leukemia development and maintenance, and thus sensitive to small-molecule inhibitors that target epigenetic mechanisms.
Experimental Design: A panel of B-ALL cell lines was tested for sensitivity to HDACi with varying isoform sensitivity.